Navigation Links
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Date:10/3/2007

le market of millions of diabetic foot infections annually with a potential estimated half billion dollar market."

Benjamin Lipsky, M.D., Professor of Medicine, University of Washington School of Medicine and Chairman of the Infectious Disease Society of America (IDSA) Guidelines Committee on Diabetic Foot Infection, commented, "I think there is a clear need for a topical antimicrobial compound for treatment of mild diabetic foot infections. Why expose the entire body to the potential toxic and microbial-altering effects of systemic therapy when the infection is limited to a superficial wound? With the growing problem of resistance of microorganisms to antibiotics, new types of antimicrobial agents and novel routes of treatment that allow lower doses of these agents would be welcomed. There are currently very few topical antimicrobial compounds available, none of which has been specifically proved to be effective for diabetic foot infections."

Under the terms of the license agreement, MacroChem will pay Genaera an initial fee of $1 million through February 1, 2008. The deal terms also include payments of $7 million to Genaera upon the achievement of certain clinical and regulatory milestones through approval, sales-based milestones of up to $35 million, and 10% royalty payments on net sales. In addition, MacroChem will assume all clinical development, manufacturing and regulatory activities for pexiganan. MacroChem will require additional funding to fully develop the product.

About Pexiganan

Pexiganan is a 22-amino acid linear peptide. It is formulated as a cream and has a novel mechanism of action based on its ability to disrupt the integrity of bacterial cell membranes. It has antimicrobial activity against Gram positive (methycillin resistant staphylococcus aureus (MRSA)) and Gram negative organisms that commonly infect skin and soft tissue. It has a low potential for induction of resistance and no cross-resistance with existing therapeuti
'/>"/>

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 ... some of our Medicare resources and continue highlighting the success of the prescription drug ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... SPRING, Md., April 19, 2011 The Food and ... the root of misuse, misprescribing, abuse, overdoses, addiction, and ... of these powerful opioids? (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251830.htm Sign up for e-mail ...
... 19, 2011 Amira Pharmaceuticals, Inc. announced today that ... an orphan drug designation by the U.S. Food and ... Commonly referred to as IPF, this fibrotic disease affects ... "This is an important development for Amira, ...
Cached Medicine Technology:Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis 2
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has been ... Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive ... by The Sisters of the Third Order of St. Francis . , Health ...
(Date:7/30/2015)... ... 30, 2015 , ... The connection between a healthy head of hair and a feeling of ... full head of hair can have a devastating impact on the daily life of a ... work place, the consequences of hair loss are not to be taken lightly. , The ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life has created ... With no water needed, the refreshing berry-flavored tablets are the perfect travel companion. ... natural ingredients that may help with body detoxification, protection and hydration,” said Mark ...
(Date:7/30/2015)... ... 30, 2015 , ... Eyepartner is proud to highlight that ... California’s Gaslamp Quarter Plaza for five years this September. , The surveillance ... for any suspicious activity. These cameras are in place to provide inarguable proof ...
(Date:7/30/2015)... ... 2015 , ... The American Telemedicine Association (ATA) is seeking ... exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 ... May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers report ... kicking off puberty in humans, a finding that offers insight ... who suffer from a rare disease that prevents the start ... family whose members have suffered from the disease confirmed that ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- ... or stroke, peripheral artery disease is often unrecognized and ... scientific statement released Wednesday. Peripheral artery disease is ... and other materials in the blood vessels outside the ...
... California reported the largest decline in drunk-driving deaths of any ... and a $232,000 grant from the California Office of Traffic ... to UC Irvine,s Health Education Center is helping to keep ... College DUI Awareness Program, UCI has organized nine universities into ...
... -- Hospitalization for underage drinking is common in the United ... estimated total cost for these hospitalizations is about $755 million ... also found geographic and demographic differences in the incidence of ... the Journal of Adolescent Health . Of ...
... potential for making medical isotopes with X-rays from a particle ... to the large scale. The Canadian Isotope Project, led by ... Research Council of Canada, and medical researchers in Winnipeg, Ottawa ... production levels with the delivery of a new particle accelerator ...
... TAMPA, Fla. A recent study conducted by researchers at ... in Rochester, Minn., has found that female cancer survivors receiving ... screening and who had never had cancer. The study ... Journal of Clinical Oncology . Researchers surveyed 19,948 women ...
Cached Medicine News:Health News:Gene Linked to Start of Puberty 2Health News:Circulatory Disorder Not Studied Enough in Women, Experts Say 2Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Canadian Isotope Project enters final stretch 2Health News:Female cancer survivors have 'worse health behaviors' than women with no cancer history 2
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone Sulfate (E1S) is the most abundant ... as normal men [1,2]. Estrone Sulfate is ... and has a longer half-life in blood ... generally parallel those of estrone and estradiol, ...
Medicine Products: